J. Goldman & CO LP Rezolute, Inc. Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Rezolute, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 232,627 shares of RZLT stock, worth $1.45 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
232,627
Previous 232,627
-0.0%
Holding current value
$1.45 Million
Previous $1.11 Million
39.22%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding RZLT
# of Institutions
84Shares Held
39.8MCall Options Held
402KPut Options Held
19.4K-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$70.3 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.38MShares$14.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.11MShares$13.2 Million1.66% of portfolio
-
Marshall Wace, LLP London, X01.85MShares$11.5 Million0.01% of portfolio
-
Blackstone Inc New York, NY1.74MShares$10.9 Million0.02% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $242M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...